Related Experiment Videos
[A case of ceftazidime-induced pneumonitis]
K Suzuki1, T Inagaki, S Adachi
1Department of Internal Medicine, Nagoya-shi Koseiin Geriatric Hospital, Japan.
Abstract:
We report a case of ceftazidime-induced pneumonitis. A 76-year-old man had been treated with cefotiam for acute pneumonia; however, he developed a high fever. On November 8, 1991, cefotiam was changed to ceftazidime and S-sulfonated human immunoglobulin. The patient showed good improvement. Four days after commencement of ceftazidime therapy, he developed chills, rigors, and high fever, with interstitial infiltrates in the right lung of his chest X-ray. On physical examination, small bubbling and crepitant rales were heard at the right lung. Once ceftazidime therapy was discontinued, he showed rapid resolution of symptoms and marked regression of the pulmonary infiltrates in the right lung of his chest X-ray. In view of the above, ceftazidime-induced pneumonitis was considered to be the diagnosis in this case. To our knowledge, there has been no previous case report of pulmonary hypersensitivity to ceftazidime. Clinicians should be alerted to the possibility of the occurrence of such a complication in patients being treated with ceftazidime.
Insights
This case report details ceftazidime-induced pneumonitis, a rare adverse reaction. Discontinuation of ceftazidime led to rapid symptom resolution, highlighting the need for clinical awareness.
Area of Science:
- Pulmonology
- Pharmacology
- Internal Medicine
Background:
- Pneumonia treatment often involves broad-spectrum antibiotics.
- Ceftazidime is a third-generation cephalosporin antibiotic used for various bacterial infections.
- Adverse drug reactions can complicate antibiotic therapy.
Observation:
- A 76-year-old male developed high fever and pulmonary infiltrates after initiating ceftazidime therapy for pneumonia.
- Physical examination revealed rales in the right lung.
- Symptoms and radiographic findings resolved rapidly upon discontinuation of ceftazidime.
Findings:
- The clinical presentation and rapid resolution suggest ceftazidime-induced pneumonitis.
- This represents a potential case of pulmonary hypersensitivity to ceftazidime.
- No prior reports of pulmonary hypersensitivity to ceftazidime were identified.
Implications:
- Clinicians should consider ceftazidime-induced pneumonitis in patients presenting with respiratory symptoms during treatment.
- Early recognition and discontinuation of the offending agent are crucial for patient recovery.
- This case underscores the importance of monitoring for rare adverse drug reactions to antibiotics.